Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – What’s Next?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares saw unusually-high trading volume on Monday . Approximately 5,485 shares were traded during mid-day trading, a decline of 39% from the previous session’s volume of 8,961 shares.The stock last traded at $16.57 and had previously closed at $17.75.

Wall Street Analysts Forecast Growth

PHAR has been the subject of a number of recent analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $30.00.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The company’s 50-day moving average price is $15.06 and its 200-day moving average price is $12.96. The company has a market cap of $1.11 billion and a P/E ratio of -1,619.38.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The firm had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. As a group, sell-side analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 52,147 shares of the company’s stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent filing with the SEC. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.